Bristol Myers Squibb’s lymphoma drug Breyanzi approved in Japan
Breyanzi is a chimeric antigen receptor (CAR) T cell therapy designed to target CD19, a biomarker for normal…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Mar 21
Breyanzi is a chimeric antigen receptor (CAR) T cell therapy designed to target CD19, a biomarker for normal…
26 Mar 21
The Phase 1/2/3 trial will evaluate two-dose mRNA vaccine BNT162b2, administered 21 days apart, in three age groups
25 Mar 21
The analysis confirmed that the AZD1222 vaccine is 76% effective against symptomatic Covid-19, and 100% against severe disease…
23 Mar 21
AZD1222 showed 79% vaccine efficacy in preventing symptomatic Covid-19 and 100% efficacy against severe Covid-19 and hospitalisation
22 Mar 21
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that keeps lymphocytes out of the blood
22 Mar 21
The new Covid-19 vaccine candidate is a virus like particle (VLP) triple antigen vaccine, which offers triple protection…
19 Mar 21
The new large-scale cell culture manufacturing facility in Holly Springs, North Carolina will create 725 jobs in the…
19 Mar 21
MHRA concluded that there is no evidence that blood clots in veins are occurring more than expected in…
18 Mar 21
Sana Biotechnology will use the iPSC cell lines from Fujifilm Cellular Dynamics to research, develop, manufacture, and commercialise…
17 Mar 21
AbbVie has acquired the portfolio of women's drugs as part of its $63bn acquisition of Allergan, completed last…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates